Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Belatacept Switch in Renal Transplant Recipients With Delayed Graft Function
NCT02134288Phase 1Terminated
- Sponsor
- The Ohio State University
- Start
- Apr 2014
- Primary completion
- Dec 2018
- Modality
- Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, randomised trial of belatacept in delayed graft function (DGF) (2 arms), sponsored by The Ohio State University. Primary endpoint: Time to recover from Delayed Graft Function at 2 weeks. Started Apr 2014; status: terminated.
02
Drugs
belatacept
03
Conditions
delayed graft function (DGF)
Beyond the preview
Go deeper on NCT02134288.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02134288.